Adjuvant trastuzumab use in high-risk breast cancer patients may prevent development of contralateral estrogen receptor-negative breast tumors

被引:2
作者
Altundag, K [1 ]
Altundag, O
Islam, R
Gundeslioglu, O
机构
[1] Hacettepe Univ, Fac Med, Inst Oncol, Dept Med Oncol, TR-06100 Ankara, Turkey
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
关键词
D O I
10.1016/j.mehy.2005.06.007
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 [基础医学];
摘要
引用
收藏
页码:1045 / 1046
页数:2
相关论文
共 3 条
[1]
Challenge in the treatment of estrogen-receptor-negative ductal carcinoma in situ [J].
Altundag, K .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) :4469-4470
[2]
ALTUNDAG K, IN PRESS TURKISH J H
[3]
Progress in chemoprevention of breast cancer [J].
Serrano, D ;
Perego, E ;
Costa, A ;
Decensi, A .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 49 (02) :109-117